Project Grant R01AG096436
Award Date 9/1/26
Completion Date 5/31/31
Dollars Obligated $638K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Tampa, FL 33612, USA
Similar Awards
- GRANT SUMMARY Texas A&M Agrilife Research received a $2.17M Project Grant from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866) to investigate the functional role of BIN1 protein in oligodendrocytes and its relationship to axonal integrity and Alzheimer's disease pathogenesis. The research will utilize oligodendrocyte-specific BIN1 conditional knockout mice to examine how loss or dysfunction of the oligodendrocyte-BIN1 axis contributes to age-associated...
- The National Institute on Aging awarded Florida State University $443,060 under the Aging Research program (CFDA 93.866) on September 1, 2026, to investigate the role of gangliosides in amyloid-beta aggregation associated with Alzheimer's disease. The research will employ biophysical experiments, in vitro solution and solid-state NMR techniques, cellular and Golgi toxicity assays, and molecular dynamics simulations to determine how free lipids modulate amyloid-beta aggregation, propagation,...
- The National Institute on Aging awarded the University of South Florida $3,331,541 on September 22, 2025, under the Aging Research program (CFDA 93.866) to conduct transcriptome-wide mapping of brain N6-methyladenosine (m6A) methylome in Alzheimer's disease. The award runs through May 31, 2030, with place of performance in Tampa, Florida. The research will create the first high-resolution reference map of brain m6A methylome in older adults using novel base-resolution quantitative m6A...
- The National Institute on Aging awarded $128,250 to Weill Medical College of Cornell University on August 5, 2026, under the Aging Research program (CFDA 93.866) to investigate modifiers of human microglia-neuron interplay in tau propagation in vivo. The research employs a human neuron-microglia chimera platform that integrates human neurons, astrocytes, and microglia into the mouse brain to model Alzheimer's disease and frontotemporal dementia pathology. Aim 1 investigates molecular...
- The National Institute on Aging, part of the Department of Health and Human Services National Institutes of Health, awarded $442,750 to the University of California, Davis on September 1, 2026, under the Aging Research program (CFDA 93.866, assistance type: Project Grant) to investigate galectin-12's role in neuroinflammation and Alzheimer's disease progression. The funded research examines how metabolic stress triggers Alzheimer's disease by enhancing inflammation, with a focus on lipid droplet...
- The National Institute on Aging awarded the University of Virginia $583,815 on August 15, 2026, under the Aging Research program (CFDA 93.866) to support research into oligodendrocyte lineage dysfunction during aging and Alzheimer's disease. The project aims to understand how myelin loss—a pathology common to both aging and Alzheimer's disease—develops in the central nervous system and to identify therapeutic targets for cognitive impairment. The research focuses on oligodendrocyte precursor...
- Federal Grant Award Summary The National Institute on Aging (NIA) awarded the University of South Florida $3.297 million under the Aging Research program (CFDA 93.866) for a four-year project period (September 1, 2025 – August 31, 2029) to develop novel peptidomimetic biomaterials that inhibit amyloid-beta (Aβ42) aggregation in Alzheimer's disease. The research deliverables include the rational design and characterization of structurally related analogues to a lead compound that stabilizes Aβ...
- The National Institute on Aging awarded Duke University $1.597 million on September 15, 2025, under the Aging Research program (CFDA 93.866) to support research on epitranscriptomic regulation of microglia in Alzheimer's disease. The research investigates how m6a methylation of adenosine residues in messenger RNA regulates microglial cell function and transitions between resting and activated states during Alzheimer's disease pathogenesis, with the goal of identifying novel...
- The National Institute on Aging awarded The Jackson Laboratory $716,579 on December 15, 2025, under the Aging Research program (CFDA 93.866) to conduct genetic dissection of microglia functions in complement-mediated synapse loss in Alzheimer's disease. The award funds basic neuroscience research examining how microglia—the brain's resident macrophages—trigger neuronal synapse loss through complement cascade activation in Alzheimer's disease models. The project addresses three knowledge gaps:...
- The National Institute on Aging awarded The Washington University $150,114 on March 18, 2026, under the Aging Research program (CFDA 93.866) to investigate the role of brain-engrafted monocyte-derived macrophages in Alzheimer's disease. The research examines how monocyte-derived macrophages infiltrating the brain contribute to Alzheimer's disease pathology. The F99 phase involves assessing the effects of promoting or depleting brain-engrafted monocyte-derived macrophages on amyloid plaque...